DNA methyltransferase (DNMT) machinery (DNMT)

The epigenetic machinery regulating DNA methylation in skin cells primarily consists of DNA methyltransferases (DNMTs), including DNMT1, DNMT3A, and DNMT3B, which catalyze the transfer of a methyl group to the C5 position of cytosine residues (Source: PMID: 23538876). In the skin, this machinery is essential for maintaining the balance between epidermal stem cell self-renewal and differentiation, ensuring proper skin barrier function and regeneration (Source: PMID: 20813266). DNMT1 is particularly vital for the proliferation of basal keratinocytes, while DNMT3A and DNMT3B contribute to de novo methylation during development and differentiation (Source: PMID: 21839685). Dysregulation of these enzymes is a hallmark of various skin pathologies, including melanoma and non-melanoma skin cancers, where hypermethylation of tumor suppressor genes promotes oncogenesis (Source: PMID: 25236393). Pharmacological targeting of this machinery using DNMT inhibitors like azacitidine and decitabine aims to reverse aberrant methylation patterns, although these treatments are currently more established in hematological malignancies than in dermatology (Source: PubChem CID 9444).

Other names

DNA methylation machineryDNA methyltransferase familyCytosine-5-methyltransferaseEpigenetic DNA modification system

Inhibition of DNA methyltransferase enzymes (DNMT1, DNMT3A, DNMT3B), leading to the depletion of these enzymes during DNA replication, resulting in DNA hypomethylation and the reactivation of epigenetically silenced genes (Source: PubChem CID 9444).